Seattle Genetics Reports on 2008 and 2009 Outlook Seattle Genetics Reports on 2008 and 2009 Outlook

Seattle Genetics Reports on 2008 and 2009 Outlook

Biotech Financial Reports 2009, March 1, 16, 3

Biotech Financial Reports
    • $5.99
    • $5.99

Publisher Description

"Our 2008 accomplishments were marked by substantial progress across our product pipeline, in particular by successfully demonstrating the therapeutic potential of SGN-35 and the promise of our antibody-drug conjugate (ADC) technology for patients with cancer," said Clay B. Siegall, Ph.D., president and CEO of Seattle Genetics. "As a result,during the first quarter of 2009 we plan to initiate a pivotal trial of SGN-35 for Hodgkin lymphoma under a special protocol assessment (SPA), which will be a major milestone for the company. We were also careful with our resources in 2008, using approximately $63 million in net cash to fund our operating activities while still advancing our programs significantly. Combined with proceeds from our recent successful public offering, we are strongly positioned to further invest in advancing our promising product pipeline." Recent and Planned Pipeline and ADC Collaborator Highlights

GENRE
Business & Personal Finance
RELEASED
2009
1 March
LANGUAGE
EN
English
LENGTH
5
Pages
PUBLISHER
Worldwide Videotex
SELLER
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
SIZE
53.3
KB

More Books Like This

Supergen has 2009 3RD Qtr Total Revenues of $10.4 Million (Financial Report) Supergen has 2009 3RD Qtr Total Revenues of $10.4 Million (Financial Report)
Supergen has 2009 3RD Qtr Total Revenues of $10.4 Million (Financial Report)
2009
Clinical Data Reports Third Qtr Fiscal 2010 Results (Financial Report) (Clinical Report) Clinical Data Reports Third Qtr Fiscal 2010 Results (Financial Report) (Clinical Report)
Clinical Data Reports Third Qtr Fiscal 2010 Results (Financial Report) (Clinical Report)
2010
Curis Reports First QTR 2008 Net Loss of $3.4 Million (Financial Report) Curis Reports First QTR 2008 Net Loss of $3.4 Million (Financial Report)
Curis Reports First QTR 2008 Net Loss of $3.4 Million (Financial Report)
2008
ABLYNX ANNOUNCES 2009 FULL YEAR RESULTS ABLYNX ANNOUNCES 2009 FULL YEAR RESULTS
ABLYNX ANNOUNCES 2009 FULL YEAR RESULTS
2010
-Morphosys AG Reports Nine Months' 2011 Results -Morphosys AG Reports Nine Months' 2011 Results
-Morphosys AG Reports Nine Months' 2011 Results
2011
GSK Publishes 2009 Corporate Responsibility Report GSK Publishes 2009 Corporate Responsibility Report
GSK Publishes 2009 Corporate Responsibility Report
2010

More Books by Biotech Financial Reports

Ing Renault F1 Team Chooses Appro Xtreme-X Supercomputer Ing Renault F1 Team Chooses Appro Xtreme-X Supercomputer
Ing Renault F1 Team Chooses Appro Xtreme-X Supercomputer
2008
Avigen Reports Net Loss of $7.3 MIL for 2nd QTR 2008 (Financial Report) Avigen Reports Net Loss of $7.3 MIL for 2nd QTR 2008 (Financial Report)
Avigen Reports Net Loss of $7.3 MIL for 2nd QTR 2008 (Financial Report)
2008
Sangamo Reports Net Loss of $7.4 MIL for 2nd QTR 2008 (Financial Report) Sangamo Reports Net Loss of $7.4 MIL for 2nd QTR 2008 (Financial Report)
Sangamo Reports Net Loss of $7.4 MIL for 2nd QTR 2008 (Financial Report)
2008
Delglobal has Fiscal 2008 3rd QTR Net Loss of $1.6 Mil (Financial Report) Delglobal has Fiscal 2008 3rd QTR Net Loss of $1.6 Mil (Financial Report)
Delglobal has Fiscal 2008 3rd QTR Net Loss of $1.6 Mil (Financial Report)
2008
Gilead Sciences Reports 2nd QTR Revenues of $1.28 Billion (Financial Report) Gilead Sciences Reports 2nd QTR Revenues of $1.28 Billion (Financial Report)
Gilead Sciences Reports 2nd QTR Revenues of $1.28 Billion (Financial Report)
2008
Curis Reports First QTR 2008 Net Loss of $3.4 Million (Financial Report) Curis Reports First QTR 2008 Net Loss of $3.4 Million (Financial Report)
Curis Reports First QTR 2008 Net Loss of $3.4 Million (Financial Report)
2008